Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations.

about

The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review

P2860

Q26785428-158BF45A-F6EE-463B-8526-E4DF45424B2D

P2860

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations.

Item

http://www.wikidata.org/entity/Q38222740

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Management options for the tre ...... il and patient considerations.

@en

type

Item

label

Management options for the tre ...... il and patient considerations.

@en

prefLabel

Management options for the tre ...... il and patient considerations.

@en

P1476

Management options for the tre ...... il and patient considerations.

@en

P2093

Bader Alsaikhan

http://www.w3.org/2001/XMLSchema#string

Khalid Alrabeeah

http://www.w3.org/2001/XMLSchema#string

Serge Carrier

http://www.w3.org/2001/XMLSchema#string

P2860

High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients

Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinic

Expression of different phosphodiesterase genes in human cavernous smooth muscle.

Sexual dysfunction in the United States: prevalence and predictors.

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.

Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract.

Comparison of phosphodiesterase type 5 (PDE5) inhibitors.

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.

Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract.

P304

271-276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IJGM.S40216

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263354886

http://www.w3.org/2001/XMLSchema#string

P698

24959092

http://www.w3.org/2001/XMLSchema#string

P932

4061160

http://www.w3.org/2001/XMLSchema#string

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations.

about

P2860

P2860

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P932